Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease

Abstract excerpt

<h4>Summary</h4> <h4>Background</h4> Improper randomization in clinical trials can result in the failure of the trial to meet its primary end-point. The last ∼10 years have revealed that common and rare genetic variants are an important disease factor and sometimes account for a substantial portion of disease risk variance. However, the burden of common genetic risk variants is not often considered in the random...

Topics

Open a Topic to create a Post that cites this publication.

• Genetic Variation
• Models, Statistical
• Neurodegenerative Diseases
• Parkinson Disease
• Parkinson's Disease Mechanisms and Treatments
• Polymorphism, Single Nucleotide
• Randomized Controlled Trials as Topic
• Risk Factors

Identifiers and source

Literature Corpus work

34c87db1-25cb-58e8-8ce2-ba951e8823f6

DOI

10.1101/427385